LAG-3 at the crossroads: A context-dependent regulator of Tregs and autoimmunity inflammatory disorders.
OpenAlex 토픽 ·
TGF-β signaling in diseases
Diabetes and associated disorders
Inflammation biomarkers and pathways
[AIMS] This review aims to systematically examine the regulatory mechanisms of Lymphocyte Activation Gene 3 (LAG3) in modulating T regulatory cell (Treg) function and its context-dependent implication
APA
Zengyang Yu, Xinyi Tang, et al. (2026). LAG-3 at the crossroads: A context-dependent regulator of Tregs and autoimmunity inflammatory disorders.. Life sciences, 394, 124359. https://doi.org/10.1016/j.lfs.2026.124359
MLA
Zengyang Yu, et al.. "LAG-3 at the crossroads: A context-dependent regulator of Tregs and autoimmunity inflammatory disorders.." Life sciences, vol. 394, 2026, pp. 124359.
PMID
41905457
Abstract
[AIMS] This review aims to systematically examine the regulatory mechanisms of Lymphocyte Activation Gene 3 (LAG3) in modulating T regulatory cell (Treg) function and its context-dependent implications in major inflammatory and autoimmune diseases.
[MATERIALS AND METHODS] We conducted a comprehensive literature review synthesizing findings from basic research, preclinical animal models, and clinical studies investigating LAG3 expression and function across autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, autoimmune diabetes, inflammatory bowel disease, and psoriasis.
[KEY FINDINGS] LAG3 exhibits dual, context-dependent roles in autoimmunity. In multiple sclerosis and rheumatoid arthritis, LAG3+ Tregs exert protective immunosuppressive functions via IL-10 and TGF-β. Conversely, in systemic lupus erythematosus and psoriasis, LAG3 expression can mark unstable Tregs transitioning to pathogenic IL-17-producing phenotypes. LAG3 also modulates Treg metabolic programming, IL-2/STAT5 signaling, and cooperates with other checkpoints like PD-1. Soluble LAG3 (sLAG-3) is elevated in several autoimmune diseases, but its functional significance remains unclear.
[SIGNIFICANCE] Understanding LAG3's context-dependent regulation of Tregs is crucial for developing precision immunotherapies. Future strategies should move beyond broad LAG3 blockade toward subset-specific modulation to restore immune tolerance in autoimmune diseases.
[MATERIALS AND METHODS] We conducted a comprehensive literature review synthesizing findings from basic research, preclinical animal models, and clinical studies investigating LAG3 expression and function across autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, autoimmune diabetes, inflammatory bowel disease, and psoriasis.
[KEY FINDINGS] LAG3 exhibits dual, context-dependent roles in autoimmunity. In multiple sclerosis and rheumatoid arthritis, LAG3+ Tregs exert protective immunosuppressive functions via IL-10 and TGF-β. Conversely, in systemic lupus erythematosus and psoriasis, LAG3 expression can mark unstable Tregs transitioning to pathogenic IL-17-producing phenotypes. LAG3 also modulates Treg metabolic programming, IL-2/STAT5 signaling, and cooperates with other checkpoints like PD-1. Soluble LAG3 (sLAG-3) is elevated in several autoimmune diseases, but its functional significance remains unclear.
[SIGNIFICANCE] Understanding LAG3's context-dependent regulation of Tregs is crucial for developing precision immunotherapies. Future strategies should move beyond broad LAG3 blockade toward subset-specific modulation to restore immune tolerance in autoimmune diseases.
MeSH Terms
Humans; Lymphocyte Activation Gene 3 Protein; Animals; T-Lymphocytes, Regulatory; Autoimmune Diseases; Inflammation; Autoimmunity; Antigens, CD
같은 제1저자의 인용 많은 논문 (5)
- Bibliometric analysis of the trends in research on the link between gut microbiota and pancreatic cancer.
- DOCK2 in Disease: Emerging Insights and Research Advances.
- The ACSL family: Bridging fatty acid metabolism and cell death in cancer progression.
- FAM117B Promotes Colorectal Cancer Progression by Enhancing DYRK1A-mediated Phosphorylation of PLK2.
- Dynamic Risk Modelling of Hepatocellular Carcinoma.